News · 26 weeks53-40%
2025-12-142026-06-07
Mix2490d
- Other11(46%)
- Insider7(29%)
- SEC Filings5(21%)
- Analyst1(4%)
Latest news
25 items- INSIDERDirector Bienaime Jean Jacques sold $203,820 worth of shares (10,500 units at $19.41) and bought $204,260 worth of shares (10,500 units at $19.45) (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 1, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 353,000 shares of common stock to twenty new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to
- PRImmunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual MeetingVaregacestat treatment resulted in statistically significant improvements in primary and all key secondary efficacy endpoints Varegacestat demonstrated statistically significant improvement in worst pain intensity at week 12, with a clinically significant difference observed as early as the first evaluation at week 4 Progression-free survival benefit was consistent across prespecified patient subgroups, including tumor location, baseline tumor size, patient age and prior systemic desmoid tumor therapy New Drug Application (NDA) for varegacestat submitted to the U.S. Food and Drug Administration (FDA) in April 2026, with Marketing Authorization Application (MAA) submission to the E
- ANALYSTBarclays initiated coverage on Immunome with a new price targetBarclays initiated coverage of Immunome with a rating of Overweight and set a new price target of $36.00
- PRImmunome to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:40 a.m. EDT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-
- INSIDERDirector Bienaime Jean Jacques bought $103,500 worth of shares (5,000 units at $20.70), increasing direct ownership by 13% to 43,415 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)
- SECSEC Form 10-Q filed by Immunome Inc.10-Q - Immunome Inc. (0001472012) (Filer)
- SECImmunome Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Immunome Inc. (0001472012) (Filer)
- PRImmunome Reports First Quarter 2026 Financial Results and Provides Business UpdateNew Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors Detailed Phase 3 RINGSIDE data selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 study ongoing for IM-1021, with initial lymphoma data expected in 2026 Investigational New Drug (IND) clearance received in April 2026 for IM-1617, a potential first-in-class solid tumor antibody-drug conjugate (ADC) Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announ
- PRImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 450,000 shares of common stock to nineteen new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to
- PRImmunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid TumorsNew Drug Application (NDA) supported by positive Phase 3 RINGSIDE results, including significant improvement in progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56% Detailed Phase 3 RINGSIDE data selected for oral presentation at the 2026 ASCO Annual Meeting Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gam
- SECSEC Form DEFA14A filed by Immunome Inc.DEFA14A - Immunome Inc. (0001472012) (Filer)
- SECSEC Form DEF 14A filed by Immunome Inc.DEF 14A - Immunome Inc. (0001472012) (Filer)
- PRImmunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual MeetingImmunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its global, Phase 3, randomized, placebo-controlled trial of varegacestat in patients with progressing desmoid tumors, has been selected for presentation in an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2, 2026, in Chicago. "The selection of the Phase 3 RINGSIDE trial for oral presentation at ASCO reflects the importance of advancing new treatment options for patients with desmoid tumors," said Clay B. Siegall, Ph.D., Presid
- INSIDERSEC Form 4 filed by Higgins Jack4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERSEC Form 4 filed by Rosett Max4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 188,500 shares of common stock to thirteen new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal
- INSIDERSEC Form 4 filed by Higgins Jack4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERSEC Form 4 filed by Siegall Clay B4 - Immunome Inc. (0001472012) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)
- INSIDERSEC Form 4 filed by Wagenheim Philip4 - Immunome Inc. (0001472012) (Issuer)
- SECSEC Form 144 filed by Immunome Inc.144 - Immunome Inc. (0001472012) (Subject)
- INSIDERDirector Bienaime Jean Jacques bought $43,670 worth of shares (2,000 units at $21.84), increasing direct ownership by 5% to 38,415 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
IMNM FAQ
7 questionsWhat does Immunome Inc. do?
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.Where does IMNM stock trade?
Immunome Inc. (IMNM) is listed on NASDAQ.What sector and industry is IMNM in?
Immunome Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immunome Inc. go public?
Immunome Inc. (IMNM) completed its IPO in 2020.What are analysts saying about IMNM?
Immunome Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $3600.00 price target on 2026-05-28. Recent price targets range from $2300.00 to $4000.00.What companies are similar to IMNM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IMNM side-by-side with any of them on Quantisnow.How can I track IMNM on Quantisnow?
Quantisnow aggregates Immunome Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMNM to receive live email and push alerts on every new disclosure.